What are the recommended empiric antibiotic regimens for pediatric patients (aged 1 month to 18 years) for common infections such as community‑acquired pneumonia, acute otitis media, skin and soft‑tissue infections, uncomplicated urinary tract infection, bacterial meningitis, and severe sepsis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Empiric Antibiotic Choices for Pediatric Patients

For most common pediatric infections, high-dose amoxicillin (90 mg/kg/day) is the preferred first-line empiric antibiotic, with specific modifications based on age, immunization status, local resistance patterns, and infection severity.

Community-Acquired Pneumonia (CAP)

Outpatient Treatment

Children < 5 years (preschool):

  • First-line: Oral amoxicillin 90 mg/kg/day divided in 2 doses 1
  • Alternative: Amoxicillin-clavulanate (amoxicillin component 90 mg/kg/day in 2 doses) 1
  • For atypical pneumonia: Azithromycin 10 mg/kg on day 1, then 5 mg/kg/day once daily on days 2-5 1
  • Duration: 5 days is as effective as 10 days for uncomplicated CAP 2

Children ≥ 5 years:

  • First-line: Oral amoxicillin 90 mg/kg/day in 2 doses (maximum 4 g/day) 1
  • If atypical pathogens cannot be distinguished: Add a macrolide to β-lactam therapy 1
  • For confirmed atypical pneumonia: Azithromycin 10 mg/kg day 1 (max 500 mg), then 5 mg/kg days 2-5 (max 250 mg) 1
  • Alternative for children > 7 years: Doxycycline 2-4 mg/kg/day in 2 doses 1

Inpatient Treatment

Fully immunized children (Hib and pneumococcal vaccines) in areas with minimal penicillin resistance:

  • First-line: IV ampicillin 150-200 mg/kg/day every 6 hours OR IV penicillin G 200,000-250,000 U/kg/day every 4-6 hours 1
  • Alternatives: Ceftriaxone 50-100 mg/kg/day every 12-24 hours OR cefotaxime 150 mg/kg/day every 8 hours 1

Not fully immunized OR high local penicillin resistance OR life-threatening infection:

  • First-line: Ceftriaxone 50-100 mg/kg/day every 12-24 hours OR cefotaxime 150 mg/kg/day every 8 hours 1
  • Add for suspected CA-MRSA: Vancomycin 40-60 mg/kg/day every 6-8 hours OR clindamycin 40 mg/kg/day every 6-8 hours (based on local susceptibility) 1

If atypical pathogens suspected (M. pneumoniae, C. pneumoniae):

  • Add to β-lactam: IV azithromycin 10 mg/kg on days 1-2, then transition to oral 1

Acute Otitis Media (AOM)

First-line: Oral amoxicillin 90 mg/kg/day in 2 doses 1, 3

  • Duration: 5 days for children ≥ 2 years with uncomplicated AOM 4
  • Duration: 10 days for children < 2 years 4

If β-lactamase-producing organisms suspected:

  • Amoxicillin-clavulanate (amoxicillin component 90 mg/kg/day in 2 doses) 1

Deferred prescribing: Consider for children ≥ 2 years with non-severe symptoms, providing prescription to fill only if symptoms worsen or fail to improve in 48-72 hours 4

Skin and Soft Tissue Infections (SSTI)

Methicillin-susceptible S. aureus (MSSA):

  • Outpatient: Oral cephalexin 75-100 mg/kg/day in 3-4 doses 1
  • Inpatient: IV cefazolin 150 mg/kg/day every 8 hours OR IV oxacillin 150-200 mg/kg/day every 6-8 hours 1

Suspected CA-MRSA (clindamycin-susceptible):

  • Outpatient: Oral clindamycin 30-40 mg/kg/day in 3-4 doses 1
  • Inpatient: IV vancomycin 40-60 mg/kg/day every 6-8 hours (target AUC/MIC >400) OR IV clindamycin 40 mg/kg/day every 6-8 hours 1

CA-MRSA (clindamycin-resistant):

  • Outpatient: Oral linezolid 30 mg/kg/day in 3 doses (children <12 years) OR 20 mg/kg/day in 2 doses (children ≥12 years) 1
  • Inpatient: IV vancomycin 40-60 mg/kg/day every 6-8 hours 1

Uncomplicated Urinary Tract Infection (UTI)

While the provided evidence focuses primarily on respiratory and skin infections, standard practice for uncomplicated UTI in children includes:

  • First-line: Oral cephalexin, cefixime, or trimethoprim-sulfamethoxazole (based on local resistance patterns)
  • Duration: 7-10 days for cystitis; 10-14 days for pyelonephritis

Bacterial Meningitis

Infants < 5 weeks:

  • First-line: IV ampicillin PLUS IV ceftriaxone or cefotaxime 5
  • Alternative: IV ampicillin PLUS IV aminoglycoside (gentamicin) 5

Children 5 weeks to 12 years:

  • First-line: IV ceftriaxone 100 mg/kg/day every 12-24 hours OR IV cefotaxime 150 mg/kg/day every 8 hours 5
  • Consider adding: IV vancomycin 40-60 mg/kg/day every 6-8 hours if highly resistant pneumococcus suspected 1
  • Adjunctive therapy: Dexamethasone for children ≥ 2 months with presumed bacterial meningitis 5

Severe Sepsis

Neonates (0-59 days):

  • First-line: IV ampicillin PLUS IV gentamicin 3
  • Alternative: IV ampicillin PLUS IV ceftriaxone or cefotaxime 6

Children > 2 months:

  • First-line: IV ceftriaxone 50-100 mg/kg/day OR IV cefotaxime 150 mg/kg/day 6
  • If MRSA suspected: Add IV vancomycin 40-60 mg/kg/day 6

Critical Considerations

Common pitfalls to avoid:

  • Excessive antibiotic duration: Most CAP cases require only 5 days of treatment, yet 67% of prescriptions exceed this 4
  • Macrolide overuse: Macrolides are not first-line for CAP in children < 5 years unless atypical pathogens are confirmed 7
  • Oral third-generation cephalosporins: These should not replace amoxicillin for uncomplicated infections due to inferior efficacy and broader spectrum 3
  • Dosing intervals: Amoxicillin should be dosed twice daily (not three times) at 90 mg/kg/day for optimal middle ear and lung penetration 1

Age-specific modifications:

  • Children < 2 months with any serious infection require hospitalization and parenteral antibiotics 6
  • Doxycycline can be used in children > 7 years for atypical pneumonia 1
  • Fluoroquinolones (levofloxacin) are reserved for children with skeletal maturity or macrolide intolerance 1

Local resistance patterns matter: In areas with high-level penicillin resistance in invasive pneumococcus, empiric third-generation cephalosporins are preferred over ampicillin/penicillin 1

References

Related Questions

What is an appropriate alternative antibiotic for a 2‑year‑old female with community‑acquired pneumonia and acute otitis media who has a rash to penicillin?
Which antibiotics should be used for a child with suspected pertussis or atypical pneumonia, and when should amoxicillin be chosen for typical bacterial pneumonia?
What is the recommended amoxicillin dosage for treating community-acquired pneumonia in adults and children?
What is the appropriate outpatient management for common infections such as uncomplicated community‑acquired bacterial pneumonia, uncomplicated cystitis in women, acute otitis media in children over 6 months, and uncomplicated cellulitis?
What is the antibiotic of choice for a three-month-old infant with bilateral pneumonia?
Which specialist should evaluate and remove an earring lodged in a patient's earlobe?
What is the recommended management of constipation in a patient taking Cobenfy (trospium‑containing antipsychotic)?
What is the recommended management for a Chiari I malformation with 9 mm tonsillar descent below the foramen magnum and fourth ventricle crowding?
How should Systane (polyethylene glycol‑propylene glycol ophthalmic solution) be administered for dry eye, including dosing, contraindications, and potential side effects?
What are the differences between induced sputum, aspirated sputum, and expectorated sputum samples?
What is the clinical significance of a low‑titer (1:20) atypical perinuclear anti‑neutrophil cytoplasmic antibody (p‑ANCA) positive indirect immunofluorescence (ANCA‑IFA) screen with negative proteinase‑3 (PR3) and myeloperoxidase (MPO) antibodies in a heavy smoker who has peripheral reticulations on chest computed tomography?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.